Loading...
XSHG
600196
Market cap8.09bUSD
May 27, Last price  
23.63CNY
1D
0.51%
1Q
-6.90%
Jan 2017
2.16%
Name

Shanghai Fosun Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
P/E
21.00
P/S
1.42
EPS
1.13
Div Yield, %
1.14%
Shrs. gr., 5y
0.77%
Rev. gr., 5y
7.52%
Revenues
41.07b
-0.80%
2,988,526,8243,102,002,4043,693,301,6783,773,234,2203,872,256,3264,555,421,6866,485,540,8007,340,782,7219,996,409,00912,025,532,04512,608,648,31414,628,820,44318,533,555,41824,918,273,56128,585,152,03330,306,981,26439,005,086,60243,951,546,89541,399,539,58841,067,195,862
Net income
2.77b
+16.08%
159,030,715259,157,973625,781,242690,856,5412,498,201,836863,653,9061,165,607,6291,563,916,4412,027,057,7362,112,869,4672,460,093,5832,805,837,0713,124,499,5492,707,923,4183,321,617,5663,662,812,9374,728,710,5273,730,804,5822,386,265,8132,769,886,631
CFO
4.48b
+2.61%
188,346,350184,914,259131,477,131233,041,247261,867,525203,362,919316,649,971665,517,0201,011,633,3741,200,214,1911,621,027,8752,110,039,2652,580,225,7752,950,105,2133,222,412,5712,579,774,3493,948,747,0094,217,570,8924,363,275,6344,476,981,262
Dividend
Aug 06, 20240.27 CNY/sh

Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
URL
https://www.fosunpharma.com/
IPO date
Aug 07, 1998
Employees
38,591
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
41,067,196
-0.80%
41,399,540
-5.81%
43,951,547
12.68%
Cost of revenue
37,972,952
33,314,223
37,631,021
Unusual Expense (Income)
NOPBT
3,094,244
8,085,317
6,320,525
NOPBT Margin
7.53%
19.53%
14.38%
Operating Taxes
656,841
369,504
626,917
Tax Rate
21.23%
4.57%
9.92%
NOPAT
2,437,403
7,715,812
5,693,608
Net income
2,769,887
16.08%
2,386,266
-36.04%
3,730,805
-21.10%
Dividends
(2,455,170)
(1,435,465)
Dividend yield
3.66%
1.56%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
18,711,315
14,728,454
17,402,869
Long-term debt
15,527,435
17,604,102
13,589,854
Deferred revenue
657,891
632,433
Other long-term liabilities
3,185,652
7,541,248
2,916,694
Net debt
(5,150,247)
(8,809,372)
(10,797,642)
Cash flow
Cash from operating activities
4,476,981
4,363,276
4,217,571
CAPEX
(5,336,705)
Cash from investing activities
(4,777,859)
Cash from financing activities
(1,326,740)
4,428,475
FCF
2,506,922
2,287,458
1,848,390
Balance
Cash
16,119,930
15,582,087
17,169,846
Long term investments
23,269,067
25,559,840
24,620,519
Excess cash
37,335,637
39,071,951
39,592,787
Stockholders' equity
41,897,007
36,846,319
38,519,031
Invested Capital
58,138,417
57,594,157
48,456,900
ROIC
4.21%
14.55%
12.53%
ROCE
3.13%
8.56%
7.00%
EV
Common stock shares outstanding
2,663,353
2,681,198
2,607,385
Price
24.85
-0.72%
25.03
-28.97%
35.24
-27.99%
Market cap
66,184,310
-1.38%
67,110,375
-26.96%
91,884,247
-26.74%
EV
73,706,686
69,232,502
90,613,057
EBITDA
6,095,787
11,203,995
8,656,437
EV/EBITDA
12.09
6.18
10.47
Interest
1,431,915
1,324,831
963,807
Interest/NOPBT
46.28%
16.39%
15.25%